Guyer Charles Greg 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
BioMarin (BMRN) EVP Greg Guyer Receives Performance RSU Award
What Happened
Greg Guyer, Executive Vice President and Chief Technical Officer of BioMarin Pharmaceutical Inc. (BMRN), was granted/awarded a total of 15,222 restricted stock units (RSUs) on Feb 25, 2026. The filing reports three award components: 6,176 RSUs, 6,675 RSUs, and 2,371 RSUs, each acquired at $0.00 (i.e., no cash payment). These RSUs are convertible into common shares on a 1:1 basis when they vest.
Key Details
- Transaction date: 2026-02-25; filing date: 2026-02-26. Price reported: $0.00 per RSU (award).
- Total RSUs awarded: 15,222 (6,176 + 6,675 + 2,371).
- Vesting: RSUs are earned but vest on March 15, 2026, contingent on Guyer's continued service through that date, with potential earlier vesting upon certain events.
- How they were earned: Awards are performance-based covering 2023–2025:
- One component tied to relative total shareholder return (TSR) (F2).
- One component tied to the number/nature of development goals achieved (F4).
- One component tied to core operating margin over specified periods (F5).
- The transaction date reflects Compensation Committee certification that the RSUs were earned (F1).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Timeliness: Filing appears timely (transaction 2/25/2026, Form 4 filed 2/26/2026); no late filing flag indicated.
Context
These are performance-based RSU awards (not a purchase or sale), so they do not involve cash changing hands now. RSUs indicate compensation tied to company performance and future service; they convert to common shares if and when they vest. For retail investors, awards reflect board/committee recognition of performance metrics being met but do not, by themselves, signal an insider buying or selling company stock.
Insider Transaction Report
- Award
Common Stock
[F1][F2][F3]2026-02-25+6,176→ 87,393 total - Award
Common Stock
[F1][F3][F4]2026-02-25+6,675→ 94,068 total - Award
Common Stock
[F1][F3][F5]2026-02-25+2,371→ 96,439 total
Footnotes (5)
- [F1]Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- [F2]Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F3]Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
- [F4]Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F5]Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.